The latest announcement is out from Fate Therapeutics (FATE).
Fate Therapeutics, Inc. has made significant strides with its innovative FT819 and FT522 therapies, targeting autoimmune diseases and B-cell malignancies. The first patient with systemic lupus erythematosus has been treated in a Phase 1 study using FT819, an off-the-shelf CAR T-cell therapy, showing promising safety and therapeutic mechanisms. Meanwhile, FT522, a CAR NK cell therapy, demonstrated rapid and sustained B-cell depletion in patients with B-cell lymphoma. These advancements were presented at the ASGCT Annual Meeting, emphasizing the company’s commitment to addressing unmet needs in autoimmune and cancer treatments.
For detailed information about FATE stock, go to TipRanks’ Stock Analysis page.
